AGC, the Tokyo-based manufacturer of glass, chemicals and high-tech materials, has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals (MPC), a subsidiary that manufactures synthetic pharmaceutical active ingredients for the group.
MPC operates at its plant in Barcelona, Spain, hence the acquisition will give AGC its first FDA-registered site in Europe in the synthetic pharmaceutical CDMO business.
MPC has vast experience manufacturing cGMP-compliant commercialised synthetic pharmaceuticals as well as compounds in clinical development on a range of scales.
Leveraging AGC's fluorination technologies and extensive experience in in-house drug discovery and the CDMO business built up in Japan, AGC, with the addition of MPC, will be able to offer its CDMO services from a broader asset base, catering to European customer requirements and expanding its presence in the European market.
The deal remains subject to approval from the relevant antitrust authorities and the fulfilment of closing conditions under the share purchase agreement.
